Radiation therapy for early breast cancer

Abstract

In women with early-stage breast cancer treated with surgery alone, microscopic residual disease may not be eliminated and can eventually cause life-threatening metastatic recurrence. Radiation therapy has been widely recommended for local control after breast-conserving surgery (BCS) and after a complete mastectomy in women at high risk of recurrence. However, even with widespread support for these recommendations within the medical community, they are not always heeded. Because local recurrence, when detected early, can often be treated with additional surgery alone, some physicians and patients still elect to avoid radiation therapy. It was felt, based upon individual trial data, that radiation therapy did not affect overall survival, but just decreased local relapse. The meta-analysis, published in the December 17/2005 Lancet, analysed individual data from 42,000 women, collected during 78 different randomised trials conducted since 1985. The availability of extensive 15-year survival data allowed the investigators to quantify the relationship between successful local control and long-term survivorship. Moreover, individual trials all show a benefit in local control and some trends toward survival advantages. The pooled meta-analysis of breast conservative surgery with or without radiation therapy Vinh Hung (2004) demonstrates a significant impact on local relapse and a small but significant impact on survival. It is considered that after BCS and in certain cases after mastectomy, radiation therapy is the standard treatment for improved local control and longterm survival.

Clinical significance of MicoRNA‐155 expression in human breast cancer

“…Radiation therapy is one of a number of treatments for breast cancer. It may be used in addition to surgery, chemotherapy, or hormone therapy 29. Like many aspects of cancer treatment, radiation therapy techniques have improved a great deal over the past decade, but radioresistance still remains a serious obstacle to successful treatment in many cases.…”

miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1

“…Breast cancer is the second leading cause of mortality among all types of cancer in women [ 1 – 3 ]. Surgical treatment and chemotherapy are the main treatment strategies for breast cancer [ 4 , 5 ]. However, many patients receiving chemotherapy exhibit a poor initial response or gradually develop resistance to chemotherapy, which is defined as multidrug resistance (MDR) and perhaps the greatest obstacle to the treatment of breast cancer.…”

γ-H2AX and other histone post-translational modifications in the clinic

“…It is estimated that between 1–5% of radiotherapy patients exhibit severe side effects, e.g., mucositis, erythema, edema, and fibrosis among others [85–87]. Therefore, there is a crucial need to find predictive markers of radiation hypersensitivity.…”